LogoBiotechNW
The life science and biotech PR distribution service

BioOutsource Ramps up Investment in R&D to Prepare for Biosimilars Boom

BioOutsource Logo

Already a Leader in Comparability of Biosimilars, New R&D Initiative Aligns BioOutsources’ Strategy with the Next Generation of Biosimilars, to Support Client Testing Requirements and Leverage Rapid Growth in Biosimilars Market

Glasgow, Scotland, UK and Cambridge, Mass., USA,  November 3, 2014 / B3C newswire / - BioOutsource Ltd. (“BioOutsource”), a global leader in biologics contract testing and biosimilar characterisation for the biopharmaceutical industry, today announced a major initiative in new research and development programs to support the next generation of biosimilars.

“We are proud to have established a reputation as one of the top providers in comparability of biosimilars,” commented BioOutsource CEO, Gerry MacKay. “For this, we are deeply appreciative of our existing clients, with whom we have worked closely to develop a range of new assays supporting early stage development.  With global biosimilar sales last year of $1.3 billion expected to explode to $35 billion by 2020, now is the time to leverage our base of knowledge and dramatically expand our R&D efforts to support the next generation of biosimilars. This investment will benefit both new and existing clients and enable them to ride the biosimilars wave with us.”

This major investment in BioOutsource’s  R&D roadmap aims to align the company’s strategy to the next generation of biosimilar molecules including Stelara (ustekinumab, for plaque psoriasis), Yervoy (ipilimumab, for melanoma), Orencia (abatacept, for rheumatoid arthritis), Synagis (palivizumab, for respiratory viral infections) and Actemra (tocilizumab, also for rheumatoid arthritis).

Mr. MacKay added, “We also plan to organize R&D Development Workshops with both current and future clients, to review future biosimilar development and align our R&D activities to support market requirements.  This is all in keeping with our over-riding client-centric focus.”

The new R&D initiative will initially be focused on establishing and validating the primary mechanism of action bioassay and affinity (surface plasmon resonance, SPR), progressing to completion of a new, full biosimilar characterisation package.

Those who would like more information about the R&D Development Workshops may send a query via this link.


About BioOutsource Ltd
BioOutsource provides contract testing services to the biopharmaceutical industry. Our core offering includes a comprehensive range of services to support the testing of Biologics, Vaccines & Biosimilars throughout their development. We possess an unparalleled combination of commercial, regulatory and technical knowledge that enables us to truly stand out as the industry’s preferred testing partner. We understand the importance of our service to support our client’s critical testing requirements and as a result, continually strive to provide a world class service globally.

 
Contacts

Gemma Fulton
Marketing Executive
BioOutsource, Ltd.
+ 44 (0) 141 946 4222  
This email address is being protected from spambots. You need JavaScript enabled to view it.

or

Bill Douglass
Gotham Communications, LLC
1-646-504-0890
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

 

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
Ok